



IFW

1614

Attorney Docket No. 17811US01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PATENT APPLICATION OF:

NICOLAS PETER SHORTIS

U.S. SERIAL NO. 10/588,558

FILING DATE: August 4, 2006


FOR: USE OF AMINOSALICYLATES IN  
DIARRHOEA-PREDOMINANT  
IRRITABLE BOWEL SYNDROME

GROUP ART UNIT:

EXAMINER: Not yet assigned.

**Certificate of Mailing**

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as first class mail, postage  
prepaid, in an envelope addressed to:  
Mail Stop Amendment, Commissioner  
for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, on December 7, 2006.

  
Jonathan R. Sick

Registration No. 43,920  
Attorney for Applicants

Customer No. 23446

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Applicant submits herewith form PTO/SB/08A listing the cited references.  
Applicant also submits herewith a copy of each of the foreign documents and  
other publications cited, for consideration by the U.S. Patent and Trademark  
Office in connection with the above application.

Also submitted herewith is a copy of the International Preliminary Report on Patentability issued on January 11, 2006, in connection with International Application No. PCT/AU2005/000142, which corresponds to the present U.S. application.

This Information Disclosure Statement is being submitted before receipt of a first Office Action on the merits of the application.

Please charge any fees incurred in connection with this submission to Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jonathan R. Sick", is written over a horizontal line.

Jonathan R. Sick  
Registration No. 43,920  
Attorney for Applicants

McANDREWS, HELD & MALLOY, LTD.  
500 West Madison Street, 34th Floor  
Chicago, Illinois 60661  
Telephone (312) 775-8000  
Facsimile (312) 775-8100

Dated: December 7, 2006



PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/588,558
				<b>Filing Date</b>	August 4, 2006
				<b>First Named Inventor</b>	Nicolas Peter Shortis
				<b>Group Art Unit</b>	
				<b>Examiner Name</b>	
				<b>Attorney Docket Number</b>	17811US01
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,519,014	05-21-1996	Borody	
	A2	6,326,364	12-04-2001	Lin, et al.	
	A3	4,556,552	12-03-1985	Porter, et al.	
	A4	4,704,295	11-03-1987	Porter, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A5	AU9187301	05-20-1992	Borody		
	A6	WO 1992/016206A	10-01-1992	Norwich Eaton Pharmaceuticals Inc.		
	A7	WO 1992/016214A	10-01-1992	Norwich Eaton Pharmaceuticals Inc.		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	A8	PARDI, D.S. et al., "Treatment of Inflammatory Bowel Disease in the Elderly: An Update" <i>Drugs &amp; Aging</i> , (2002) pp. 355-363, Vol. 19, No. 5
	A9	GIAFFER, M.H. et al., "Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine" <i>Alimentary Pharmacology &amp; Therapeutics</i> (1992), pp. 51-59, Vol. 6, No. 1
	A10	STEIN, R.B. et al., "Comparative Tolerability of Treatments for Inflammatory Bowel Disease" <i>Drug Safety</i> , (2000) pp. 429-448, Vol. 23, No. 5
	A11	W. KRUIS, "A comparison of two different doses of balsalazide and one dose of mesalazine in chronic treatment of ulcerative colitis" <i>Gastroenterology</i> (1998), p. A1014, Vol. 114

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.*